Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice

Vaccine

Volumn 25, Issue 44, 2007, Pages 7664-7673

  Zhao, Wenfeng ^a   Wu, Wutong ^a   Xu, Xudong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Fusion peptide; Helicobacter pylori; Liposome vaccine; Oral vaccine; Urease

Indexed keywords

CHOLERA TOXIN B SUBUNIT; FUSION PEPTIDE CTUBE; HELICOBACTER PYLORI VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOSOME; UNCLASSIFIED DRUG; UREASE; UREASE B EPITOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM COLONY; BACTERIUM CULTURE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; VACCINATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHOLERA TOXIN; EPITOPES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INTERFERON TYPE II; INTERLEUKIN-4; LIPOSOMES; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; UREASE; VACCINATION; VACCINES, SYNTHETIC;

EID: 35148839222     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.034     Document Type: Article

References (43)

1. Blaser M.J. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 161 4 (1990) 626-633
2. Nomura AGN, Stemmermann PH, Chyou I, Kato GI, Perez-Perez, MJ Blaser. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325(16):1132-6.
3. Parsonnet J., Hansen S., Rodriguez L., Gelb A.B., Warnke R.A., Jellum E., et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330 18 (1994) 1267-1271
4. Dunn B.E., Cohen H., and Blaser M.J. Helicobacter pylori. Clin Microbiol Rev 10 4 (1997) 720-741
5. Brown L.M. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22 2 (2000) 283-297
6. Unge P. Antibiotic treatment of Helicobacter pylori infection. Curr Top Microbiol Immunol 241 (1999) 261-300
7. Boyanova L., Mentis A., Gubina M., Rozynek E., Gosciniak G., Kalenic S., et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 8 7 (2002) 388-396
8. Koletzko S., Richy F., Bontems P., Crone J., Kalach N., Monteiro M.L., et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 55 12 (2006) 1711-1716
9. Wheeldon T.U., Hoang T.T., Phung D.C., Bjorkman A., Granstrom M., and Sorberg M. Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther 21 8 (2005) 1047-1053
10. Glupczynski Y. Antimicrobial resistance in Helicobacter pylori: a global overview. Acta Gastroenterol Belg 61 3 (1998) 357-366
11. Del Giudice G., Covacci A., Telford J.L., Montecucco C., and Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 19 (2001) 523-563
12. Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12 2 (2007) 89-102
13. Dunn B.E., Campbell G.P., Perez-Perez G.I., and Blaser M.J. Purification and characterization of urease from Helicobacter pylori. J Biol Chem 265 16 (1990) 9464-9469
14. Hu L.T., and Mobley H.L.T. Purification and N-terminal analysis of urease from Helicobacter pylori. Infect Immun 58 4 (1990) 992-998
15. Evans Jr. D.J., Evans D.G., Kirkpatrick S.S., and Graham D.Y. Characterization of the Helicobacter pylori urease and purification of its subunits. Microb Pathog 10 1 (1991) 15-26
16. Nagata K., Mizuta T., Tonokatu Y., Fukuda Y., Okamura H., Hayashi T., et al. Monoclonal antibodies against the native urease of Helicobacter pylori: synergistic inhibition of urease activity by monoclonal antibody combinations. Infect Immun 60 11 (1992) 4826-4831
17. Hirota K., Nagata K., Norose Y., Futagami S., Nakagawa Y., Senpuku H., et al. Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production. Infect Immun 69 11 (2001) 6597-6603
18. Iizumi T., Yamanishi S., Kumagai Y., Nagata K., Kamiya S., Hirota K., et al. Augmentation of Helicobacter pylori urease activity by its specific IgG antibody: implications for bacterial colonization enhancement. Biomed Res 26 1 (2005) 35-42
19. Ha N.C., Oh S.T., Sung J.Y., Cha K.A., Lee M.H., and Oh B.H. Supramolecular assembly and acid resistance of Helicobacter pylori urease. Nat Struct Biol 8 6 (2001) 505-509
20. Lycke N. The mechanism of cholera toxin adjuvanticity. Res Immunol 148 8-9 (1997) 504-520
21. Holmagren J., Czerkinsky C., Lycke N., and Svennerholm A.M. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am J Trop Med Hyg 50 5 (1994) 42-54
22. Holmgren J., Lycke N., and Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11 12 (1993) 1179-1184
23. Park S.J., Chun S.K., and Kim P.H. Intraperitoneal delivery of cholera toxin B subunit enhances systemic and mucosal antibody responses. Mol Cells 16 1 (2003) 106-112
24. Bergquist C., Johansson E.L., Lagergard T., Holmgren J., and Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 65 7 (1997) 2676-2684
25. Jertborn M., Svennerholm A.M., and Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10 2 (1992) 130-132
26. Holmgren J., Svennerholm A.M., Jertborn M., Clemens J., Sack D.A., Salenstedt R., et al. An oral B subunit: whole cell vaccine against cholera. Vaccine 10 13 (1992) 911-914
27. Felnerova D., Viret J.F., Glck R., and Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 15 6 (2004) 518-529
28. Gregoriadis G., Gursel I., Gursel M., and McCormack B. Liposome as immunological adjuvants and vaccine carrier. J Control. Release 41 (1996) 49-56
29. Gregoriadis G., McCormack B., Obrenovic M., Saffie R., Zadi B., and Perrie Y. Vaccine entrapment in liposomes. Methods 19 (1999) 156-162
30. Majumder R., Sengupta S., Khetawat G., Bhadra R.K., Roychoudhury S., and Das J. Physical map of the genome of Vibrio cholerae 569B and localization of genetic markers. J Bacteriol 178 4 (1996) 1105-1112
31. Sazoka F.C., and Papahadjopoulos D. Procedure for the preparation of liposomes with large aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 75 9 (1978) 4194-4198
32. Kleanthous H., Myers G.A., Georgakopoulos K.M., Tibbitts T.J., Ingrassia J.W., Gray H.L., et al. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun 66 6 (1998) 2879-2886
33. Ferrero R.L., Thiberge J.M., Huerre M., and Labigne A. Immune responses of specific-pathogen-free mice to chronic Helicobacter pylori (strain SS1) infection. Infect Immun 66 4 (1998) 1349-1355
34. Guy B., Hessler C., Fourage S., Haensler J., Vialon-Lafay E., Rokbi B., et al. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 16 8 (1998) 850-856
35. Mattsson A., Tinnert A., Hamlet A., Lonroth H., Bolin I., and Svennerholm A.M. Specific antibodies in sera and gastric aspirates of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Clin Diagn Lab Immunol 5 3 (1998) 288-293
36. Johansson E.L., Rask C., Fredriksson M., Eriksson K., Czerkinsky C., and Holmgren J. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 66 2 (1998) 514-520
37. Corthesy-Theulaz I., Porta N., Glauser M., Saraga E., Vaney A.C., Haas R., et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 109 1 (1995) 115-121
38. Ermak T.H., Giannasca P.J., Nichols R., Myers G.A., Nedrud J., Weltzin R., et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC Class II-restricted responses. J Exp Med 188 12 (1998) 2277-2288
39. Irie T., Watarai S., Iwasaki T., and Kodama H. Protection against experimental Aeromonas salmonicida infection in carp by oral immunisation with bacterial antigen entrapped liposomes. Fish Shellfish Immunol 18 (2005) 235-242
40. Areas A.P., Oliveira M.L., Miyaji E.N., Leite L.C., Aires K.A., Dias W.O., et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun 321 1 (2004) 192-196
41. Harakuni T., Sugawa H., Komesu A., Tadano M., and Arakawa T. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect Immun 73 9 (2005) 5654-5665
42. Shi C.H., Cao C., Xhig J.S., Li J., and Ma Q.J. Gene fusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusion protein. Vaccine 13 10 (1995) 933-937
43. Smythiesa L.E., Novakb M.J., Waitesc K.B., Lindseyd J.R., Morrowb C.D., and Smith P.D. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 23 7 (2005) 901-909